About Us
Products
Responsibility
Investors
Media
Careers
Worldwide
- North America
  - USA
  - Canada
  - Mexico
- South America
  - Brazil
  - Peru
- Asia Pacific
  - India
  - Bangladesh
  - Thailand
  - Malaysia
  - Singapore
  - Myanmar
  - Sri Lanka
  - Japan
  - China
- Europe
  - Denmark
  - Finland
  - France
  - Germany
  - Hungary
  - Italy
  - Norway
  - Poland
  - Romania
  - Spain
  - Sweden
  - Switzerland
  - The Netherlands
  - The United Kingdom & Ireland
- Middle East
  - UAE
- Africa
  - Morocco
  - Nigeria
  - South Africa
  - Egypt
  - Kenya
- Oceania
  - Australia & New Zealand
- CIS
  - Russia
  - Ukraine
Contact Us

Select Page

Test Form

Please enable JavaScript in your browser to complete this form.

Name *

First

Last

Email *

or Email Comment

Comment or Message

Search for:

Recent Posts

Sun Pharma receives approval to manufacture and market semaglutide in Brazil
Sun Pharma launches generic semaglutide in South Africa
Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition
Revital Brings a Fresh Perspective to India’s Conversation Around Everyday Fatigue
Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa

Recent Comments

About Sun Pharma
- Vision & Values
- Milestones & Recognitions
Operations
Investors
Work with us
- Careers
- Current Openings
Quick Links

Facebook
X
Instagram
Linkdin
Instagram

Copyright © Sun Pharmaceutical Industries Ltd. Privacy Policy | Disclaimer

Top

Important Notice

As per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 it is mandatory for all the shareholders holding shares in physical form to update their KYC and other details.